BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11782694)

  • 1. Naftidrofuryl in quality of life (NIQOL). A Belgian study.
    D'Hooge D; Lehert P; Clement DL
    Int Angiol; 2001 Dec; 20(4):288-94. PubMed ID: 11782694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naftidrofuryl can enhance the quality of life in patients with intermittent claudication.
    Spengel F; Brown TM; Poth J; Lehert P
    Vasa; 1999 Aug; 28(3):207-12. PubMed ID: 10483329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program.
    Spengel F; Clément D; Boccalon H; Liard F; Brown T; Lehert P
    Int Angiol; 2002 Mar; 21(1):20-7. PubMed ID: 11941270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS).
    Kieffer E; Bahnini A; Mouren X; Gamand S
    Int Angiol; 2001 Mar; 20(1):58-65. PubMed ID: 11342997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study.
    Adhoute G; Andreassian B; Boccalon H; Cloarec M; Di Maria G; Lefebvre O; Mondine P; Plagnol P; Pointel JP; Quancard X
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S75-80. PubMed ID: 1369725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl.
    Moody AP; al-Khaffaf HS; Lehert P; Harris PL; Charlesworth D
    J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S44-7. PubMed ID: 7517477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Double-blind randomized comparative study of nicergoline naftidrofuryl on the quality of life in chronic obliterative arteriopathy of lower limbs with intermittent claudication].
    Meilhac B; Montestruc F; Aubin F; Djian F; Rouffy J
    Therapie; 1997; 52(3):179-86. PubMed ID: 9366101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naftidrofuryl in intermittent claudication: a retrospective analysis.
    Lehert P; Comte S; Gamand S; Brown TM
    J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S48-52. PubMed ID: 7517478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intermittent claudication and quality of life. Psychometric validation of the French version of the CLAU-S questionnaire].
    Boccalon H; Lehert P; Comte S
    J Mal Vasc; 2000 Apr; 25(2):98-107. PubMed ID: 10804390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naftidrofuryl: a review of its use in the treatment of intermittent claudication.
    Goldsmith DR; Wellington K
    Drugs Aging; 2005; 22(11):967-77. PubMed ID: 16323973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of naftidrofuryl on intermittent claudication: a meta-analysis.
    Lehert P; Riphagen FE; Gamand S
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S81-6. PubMed ID: 1369727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the efficacy and tolerance of naftidrofuryl in patients presenting with exertional angina. Multicenter double-blind versus placebo study].
    Hirsch JL; Bensoussan JJ; Mosnier M; Lehert P
    Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):137-45. PubMed ID: 12555338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Consequences of obliterating arteriopathy of the legs on the professional activity of patients and external assistance].
    Rolland N; Lebrun T; Comte S; Sailly JC
    J Mal Vasc; 1999 Jun; 24(3):208-13. PubMed ID: 10467531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naftidrofuryl for intermittent claudication.
    de Backer TL; Vander Stichele R; Lehert P; Van Bortel L
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD001368. PubMed ID: 23235580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data.
    De Backer T; Vander Stichele R; Lehert P; Van Bortel L
    BMJ; 2009 Mar; 338():b603. PubMed ID: 19276131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of iloprost in patients with intermittent claudication.
    Creager MA; Pande RL; Hiatt WR
    Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparan sulfate in the treatment of intermittent claudication: results of a randomized, double-blind, placebo-controlled multicenter trial.
    Messa GL; Gelso E
    Drugs Exp Clin Res; 2002; 28(1):37-48. PubMed ID: 12073766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study.
    Nenci GG; Gresele P; Ferrari G; Santoro L; Gianese F;
    Thromb Haemost; 2001 Nov; 86(5):1181-7. PubMed ID: 11816704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naftidrofuryl for intermittent claudication.
    De Backer TL; Vander Stichele R; Lehert P; Van Bortel L
    Cochrane Database Syst Rev; 2008 Apr; (2):CD001368. PubMed ID: 18425872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg.
    Adhoute G; Bacourt F; Barral M; Cardon JM; Chevalier JM; Cuny A; Gillet M; Juhan C; Leguay G; Marion J
    Angiology; 1986 Mar; 37(3 Pt 1):160-7. PubMed ID: 3518547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.